Novel approach for UPLC-ESI-Tandem mass spectrometric method for simultaneous determination of olmesartan medoxomil and hydrochlorothiazide in their pharmaceutical combination with kinetic studies of forced degradation
Open Access
- 30 September 2016
- journal article
- Published by European Journal of Chemistry in European Journal of Chemistry
- Vol. 7 (3), 309-314
- https://doi.org/10.5155/eurjchem.7.3.309-314.1450
Abstract
A simple, robust ultra-performance liquid chromatography coupled to ESI-Tandem mass spectrometric (UPLC-MS/MS) technique was developed for the simultaneous quantitation of olmesartan medoxomil (OLM) and hydrochlorothiazide (HCT) in bulk and their combined pharmaceutical formulation. Chromatographic separation was done on a Hypersil gold 50×2.1 mm (1.9 μm) column, with gradient elution of mobile phase consisted of acetonitrile and 0.1% formic acid aqueous solution. Detection of analytes was carried out using selective reaction monitoring (SRM) mode on a triple quadrupole mass spectrometer coupled with electrospray ionization (ESI). Linearity was achieved over concentration ranges of 2.0-200.0 and 3.0-50.0 ng/mL for OLM and HCT, respectively. Intra and inter day reproducibility were acceptable. The lower limits of detection were found to be 0.627 and 0.583 ng/mL and lower limits of quantitation were 1.900 and 1.767 ng/mL for OLM and HCT, respectively. The method was successfully applied for determination the cited drugs in their combined pharmaceutical dosage form. The method was applied to study the kinetic of forced degradation of both drugs under different conditions. The method was validated according to ICH guidelines and there is no significance difference between the proposed method and the reported method. The simplicity and sensitivity of this method allows the utilization of method in quality control of the cited drugs.Keywords
This publication has 18 references indexed in Scilit:
- Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kineticsAnalytical and Bioanalytical Chemistry, 2014
- Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2014
- Spectrophotometric methods for simultaneous determination of ternary mixture of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazideSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2014
- Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practiceVascular Health and Risk Management, 2013
- A novel approach for nanoemulsion components screening and nanoemulsion assay of olmesartan medoxomil through a developed and validated HPLC methodRSC Advances, 2013
- Application of smart spectrophotometric methods and artificial neural network for the simultaneous quantitation of olmesartan medoxamil, amlodipine besylate and hydrochlorothiazide in their combined pharmaceutical dosage formChemistry Central Journal, 2013
- Spectrophotometric estimation of olmesartan medoxomil and hydrochlorothiazide in tabletIndian Journal of Pharmaceutical Sciences, 2010
- Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertensionJournal of Hypertension, 2005
- Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazideAmerican Journal of Hypertension, 2004
- The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interactionJournal of Hypertension, 2001